Acting on the cytokine cascade is key to preventing disease progression and death in
hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 …

The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid
development of clinical trials targeting this cytokine. Overall, these trials do not support the …

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a
dysregulated hyperinflammatory response. Areas covered Authors review evidence on IL-6 …

At present, there are no proven agents for treatment of coronavirus disease (COVID-19). The
available evidence has not allowed guidelines to clearly recommend any drugs outside the …

Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases
or treatment of malignancies; it may also appear during the progression of COVID-19. CSS …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a new member of the
coronavirus family that can cause coronavirus disease 2019 (COVID‐19). COVID‐9 has …

The epidemic due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
infection has been spreading globally, raising increasing concerns. This public health …

COVID-19 mortality is strongly associated with the development of severe pneumonia and
acute respiratory distress syndrome with the worst outcome resulting in cytokine release …

Abstract Since 2019, COVID-19 has become the most important health dilemma around the
world. The dysregulated immune response which results in ARDS and cytokine storm has …

Background: Interleukin-6 (IL-6) is known to be detrimental in coronavirus disease 2019
(COVID-19) because of its involvement in driving cytokine storm. This systematic review and …